Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POL6326 for Stem Cell Mobilization in Hematological Malignancies
NCT01413568Phase 2Completed
- Sponsor
- Polyphor
- Start
- Apr 2012
- Primary completion
- Nov 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of balixafortide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), sponsored by Polyphor. Started Apr 2012; status: completed.
02
Drugs
balixafortide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01413568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01413568.